Skip to main content
SpringerLink
Log in

Clinical Trials and Transethnic Pharmacology

  • Review Articles
  • Drug Safety Concepts
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

It is generally agreed that the advance of a global economy must be accompanied by global drug development. Thus, more intense effort, time and expense must be given to the study of overall global population, which will ultimately be exposed to the drug in development. Race and ethnicity of the ultimate drug consumer must be evaluated, and not only in broad terms. Ethnic and racial representations must be considered in clinical trials.

The differences in response to drug action in various ethnic and racial groups must be evaluated to provide information for the physician in practice, who is faced with an increasingly nonhomogeneous population, and who must prescribe medications for those patients.

The practising physician urgently requires international, crosscultural collaborative studies, using standardised methods applicable to different cultural settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lin TY. Multiculturalism and Canadian psychiatry: opportunities and challenges. Can J Psychiatry 1986; 31: 681–90

    PubMed  CAS  Google Scholar 

  2. Jenkins JH, Karno M, de la Selva A, et al. Expressed emotion of relatives, maintenance drug treatment, and relapse in schizophrenia and mania. Psychopharmacol Bull 1986; 22: 621–7

    PubMed  CAS  Google Scholar 

  3. Light KC, Sherwood A. Race, borderline hypertension, and hemodynamic responses to behavioral stress before and after beta-adrenergic blockade. Health Psychol 1989; 8: 577–95

    PubMed  CAS  Google Scholar 

  4. Falkner B, Kushner H. Race differences in stress-induced reactivity in young adults. Health Psychol 1989; 8: 613–27

    PubMed  CAS  Google Scholar 

  5. Myers HF, Shapiro D, McClure F, et al. Impact of caffeine and psychological stress on blood pressure in Black and White men. Health Psychol 1989; 8: 597–612

    PubMed  CAS  Google Scholar 

  6. Gibson RC. Race and the self-reported health of elderly persons. J Gerontol Soc Sci 1991; 46: S235–42

    CAS  Google Scholar 

  7. Rushing B, Ritter C, Burton RPD. Race differences in the effects of multiple roles on health: longitudinal evidence from a national sample of older men. J Health Soc Behav 1992; 33: 126–39

    PubMed  CAS  Google Scholar 

  8. Holzman Kleinman P, Lukoff IF. Ethnic differences in factors related to drug use. J Health Soc Behav 1978; 19: 190–9

    Google Scholar 

  9. Wood WD, Sherrets SD. Race as a factor in the perceived importance of the use of psychotropic medication. J Psychiatr Res 1982–83; 17:297–301

    PubMed  Google Scholar 

  10. Wilson MR. Glaucoma in Blacks: where do we go from here? JAMA 1989; 261: 281–2

    PubMed  CAS  Google Scholar 

  11. McPeek M, Salkowitz J, Laufman H, et al. The expression of HLA-DR by monocytes from Black and from White donors: different requirements for protein synthesis. Clin Exp Immunol 1992; 87: 163–8

    PubMed  CAS  Google Scholar 

  12. Downing RW, Rickeis K. Responders and nonresponders to chlordiazepoxide and placebo: a discriminant function analysis. Prog Neuropsychopharmacol Biol Psychiatry 1980; 4: 405–15

    CAS  Google Scholar 

  13. Chen KK, Poth EJ. Racial differences as illustrated by the mydriatic action of cocaine, euphthalmine, and ephedrine. J Pharmacol Exp Ther 1929; 36: 429–45

    CAS  Google Scholar 

  14. Garde JF, Aston R, Endler GC, et al. Racial mydriatic response to belladonna premedication. Anesth Analg 1978; 57: 572

    PubMed  CAS  Google Scholar 

  15. Sirgio MA, Cook CA, Modrak JB. Hypertensive therapy in Blacks: significance of pathophysiologic observations. J Clin Hypertens 1986; 1: 1–6

    Google Scholar 

  16. Walle T, Byington RP, Furberg CD, et al. Biological determinants of propranolol disposition: results from 1308 patients in the beta-blocker heart attack trial. Clin Pharmacol Ther 1985; 38: 509–18

    PubMed  CAS  Google Scholar 

  17. Kalow W, Goedde HW, Agarwal DP, editors. Ethnic differences in reactions to drugs and xeonobiotics. New York: Alan Liss Inc, 1986

    Google Scholar 

  18. Svensson CK. Representation of American Blacks in clinical trials of new drugs. JAMA 1989; 261: 263–5

    PubMed  CAS  Google Scholar 

  19. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350–73

    PubMed  CAS  Google Scholar 

  20. Denber HCB. Different doses of neuroleptics for genetically different groups [letter]. Am J Psychiatry 1984; 141 (1): 156–7

    Google Scholar 

  21. Anonymous. EC doctors’ attitudes - no change? SCRIP 1992; 1769: 6

  22. Ghoneim MM, Kortilla K, Chiang CH, et al. Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 1981; 29: 749–56

    PubMed  CAS  Google Scholar 

  23. Vesell ES. The influence of host factors on drug response. I. Ethnic background. Ration Drug Ther 1979; 13: 1–6

    PubMed  CAS  Google Scholar 

  24. Vesell ES. Why are toxic reactions to drugs so often undetected initially? N Engl J Med 1980; 302: 1027–9

    PubMed  CAS  Google Scholar 

  25. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet 1982; 7: 373–400

    PubMed  CAS  Google Scholar 

  26. Kalow W. Genetics of drug transformation. Clin Biochem 1986; 19: 76–82

    PubMed  CAS  Google Scholar 

  27. Midha KK, Hawes EM, Hubbard JW, et al. A pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacol Bull 1988; 95: 333–8

    CAS  Google Scholar 

  28. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985; 29: 342–75

    PubMed  CAS  Google Scholar 

  29. Horai Y, Zhou HH, Zhang LM, et al. N-acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol 1988; 25: 81–7

    PubMed  CAS  Google Scholar 

  30. Jacqz R, Hall SD, Branch RA. Geneticaly determined polymorphism in drug oxidation. Hepatology 1986; 6: 1020–32

    PubMed  CAS  Google Scholar 

  31. Lou YC, Liu Y, Bertilsson L, et al. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987; 2: 852–3

    PubMed  CAS  Google Scholar 

  32. Rudorfer MV, Lane EA, Chang WH, et al. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 27: 433–40

    Google Scholar 

  33. Woolhouse NM, Andoh B, Mahgoub A, et al. Debrisoquine hydroxylation polymorphism among Ghanians and Caucasians. Clin Pharmacol Ther 1979; 26: 584–91

    PubMed  CAS  Google Scholar 

  34. Andoh B, Idle JR, Sloan TP, et al. Inter-ethnic differences and inter-phenotype differences among Ghanians and Caucasians in the metabolic hydroxylation of phenytoin. Br J Clin Pharmacol 1980;9:282P–283P

    PubMed  CAS  Google Scholar 

  35. Woolhouse NM, Adjepon-Yamoah KK, Mellstroem B, et al. Nortriptyline and debrisoquine hydroxylations in Ghanian and Swedish subjects. Clin Pharmacol Ther 1984; 36: 374–8

    PubMed  CAS  Google Scholar 

  36. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism — clinical aspects. Pharmacol Ther 1990; 46: 377–94

    PubMed  CAS  Google Scholar 

  37. Horai Y, Ishizaki T. Pharmacogenetics and its clinical implications. Part II: oxidation polymorphism. Ration Drug Ther 1988; 22: 1–8

    PubMed  CAS  Google Scholar 

  38. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12: 102–7

    PubMed  CAS  Google Scholar 

  39. Lou YC. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab Rev 1990; 22: 451–75

    PubMed  CAS  Google Scholar 

  40. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198–207

    PubMed  CAS  Google Scholar 

  41. Iyun AO, Lennard MS, Tucker GT, et al. Metoprolol and debrisoquine metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986; 40: 387–95

    PubMed  CAS  Google Scholar 

  42. McGourty JC, Silas JH, Lennard MS, et al. Metoprolol metabolism and debrisoquine oxidation polymorphism — population and family studies. Br J Clin Pharmacol 1986; 20: 555–66

    Google Scholar 

  43. Sohn DR, Shin SG, Park CW, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32: 504–7

    PubMed  CAS  Google Scholar 

  44. Steiner E, Iselius L, Alvan G, et al. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985; 38: 394–401

    PubMed  CAS  Google Scholar 

  45. Ward SA, Goto F, Nakamura K, et al. S-Mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin Pharmacol Ther 1987; 42: 96–9

    PubMed  CAS  Google Scholar 

  46. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the inter-phenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160–9

    PubMed  CAS  Google Scholar 

  47. Ellard GA. Variation between individuals and populations in acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976; 19: 610–25

    PubMed  CAS  Google Scholar 

  48. Ama PFM, Poehlman ET, Simoneau JA, et al. Fat distribution and adipose tissue metabolism in non-obsese male black African and Caucasian subjects. Int J Obes 1986; 10: 503–10

    PubMed  CAS  Google Scholar 

  49. Glassman AH, Roose SR. Tricyclic antidepressant tolerance in Oriental and Occidental populations. Psychopharmacol Bull 1979; 15 (4): 41–4

    PubMed  CAS  Google Scholar 

  50. Langford HG, Cushman WC, Hsu H. Chronic effect of KC1 on Black-White differences in plasma renin activity, aldosterone, and urinary electrolytes. Am J Hypertens 1991; 4: 399–403

    PubMed  CAS  Google Scholar 

  51. Joubert PH, Brandt HD. Apparent racial differences in response to angiotensin I infusion. Eur J Clin Pharmacol 1990; 39: 183–5

    PubMed  CAS  Google Scholar 

  52. Agarwal DP, Goedde HW. Ethanol oxidation: ethnic variations in metabolism and response. Prog Clin Biol Res 1986; 214: 99–112

    PubMed  CAS  Google Scholar 

  53. Wolff PH. Ethnic differences in alcohol sensitivity. Science 1972; 175: 449–50

    PubMed  CAS  Google Scholar 

  54. Ho SB, De Master EG, Shafter RB, et al. Opiate antagonist nalmefeme inhibits ethanol-induced flushing in Asians: a preliminary study. Alcohol Clin Exp Res 1988; 12: 706–12

    Google Scholar 

  55. Monteiro MG, Klein JL, Schuckit MA. High levels of sensitivity to alcohol in young adult Jewish men: a pilot study. J Stud Alcohol 1991; 52: 464–9

    PubMed  CAS  Google Scholar 

  56. Schukit MA. Biological vulnerability to alcoholism. J Cons Clin Psychol 1987; 55: 301–9

    Google Scholar 

  57. Schukit MA, Gold EO. A simultaenous evaluation of multiple markers of ethanol/placebo challenges in sons of alcoholics and controls. Arch Gen Psychiatry 1988; 45: 211–6

    Google Scholar 

  58. Clark WC, Clark SB. Pain response in Nepalese porters. Science 1980; 209: 410–2

    PubMed  CAS  Google Scholar 

  59. Zborowski M. Cultural components in response to pain. J Soc Issues 1952; 8: 16–30

    Google Scholar 

  60. Wolff BB, Langley S. Cultural factors and the response to pain. Am Anthropologist 1968; 70: 494–501

    Google Scholar 

  61. Lipton JA, Marbach JJ. Ethnicity and the pain experience. Soc Sci Med 1984; 19: 1279–8

    PubMed  CAS  Google Scholar 

  62. Streltzer J, Wade TC. The influence of cultural group on the undertreatment of postoperative pain. Psychosom Med 1981; 53: 397–403

    Google Scholar 

  63. Houghton IT, Aun CST, Gin T, et al. Inter-ethnic differences in post-operative pethidine requirements. Anaesth Intens Care 1992; 20: 52–5

    CAS  Google Scholar 

  64. Yue QY, Svensson JO, Alm C, et al. Interindividual and interethnic differences in the demthylation and glucoronidation of codeine. Br J Clin Pharmacol 1989; 28: 629–37

    PubMed  CAS  Google Scholar 

  65. Mucklow JC, Fraser HS, Bulpitt CJ, et al. Environmental factors affecting paracetamol metabolism in London factory and office workers. Br J Clin Pharmacol 1980; 10: 67–74

    PubMed  CAS  Google Scholar 

  66. Sommers DeK, van Staden DA, Moncrieff J, et al. Paracetamol metabolism in African villagers. Human Toxicol 1985; 4: 385–9

    CAS  Google Scholar 

  67. Critchley JAJH, Nimmo GR, Gregson CA, et al. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol 1986; 22: 649–57

    PubMed  CAS  Google Scholar 

  68. Ko YK. Pharmacokinetics of paracetamol in the Chinese and Indians living in Signapore [MS thesis]. Singapore: Department of Pharmacology, National University of Signapore, 1985

    Google Scholar 

  69. Aronoff SL, Bennett PH, Hamman RF, et al. Unexplained hyperinsulinemia in normal and ‘prediabetic’ Pima Indians compared with normal Caucasians: an example of racial differences in insulin secretion. Diabetes 1977; 26: 827–40

    PubMed  CAS  Google Scholar 

  70. Haffner SM, Stern MP, Hazuda HP, et al. Hyperinsulinemia in a population at high risk for non-insulin dependent diabetes mellitus. N Engl J Med 1986; 315: 220–4

    PubMed  CAS  Google Scholar 

  71. Stern MP, Gaskill SP, Hazuda HP, et al. Does obesity explain excess prevalence in diabetes among Mexican Americans? Results of the San Antonio Heart Study. Diabetologia 1983; 24: 272–7

    PubMed  CAS  Google Scholar 

  72. Haffner SM, Stern MP, Dunn J, et al. Diminished insulin sensitivity and increased insulin response in nonobese, nondiabetic Mexican Americans. Metabolism 1990; 39: 842–7

    PubMed  CAS  Google Scholar 

  73. Caralis PV. Hypertension in the Hispanic-American population. Am J Med 1990; 88 Suppl. 3B: 9S–16S

    PubMed  CAS  Google Scholar 

  74. Cooper ES, Caplan LR. Cerebrovascular disease in hypertensive Blacks. Cardiovasc Clin 1991; 21 (3): 145–55

    PubMed  CAS  Google Scholar 

  75. Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. Am J Cardiol 1988; 61: 46H–52H

    PubMed  CAS  Google Scholar 

  76. Messerli FH, Schmieder RE. Use of diuretic agents in obese or black patients with systemic hypertension. Am J Cardiol 1986; 58: 11A–14A

    PubMed  CAS  Google Scholar 

  77. Parmer RJ, Cervenka JH, Stone RA, et al. Autonomic function in hypertension: are there racial differences? Circulation 1990; 81: 1305–11

    PubMed  CAS  Google Scholar 

  78. Aviv A, Aladjem M. Essential hypertension in blacks: epidemiology, characteristics, and possible roles of racial differences in sodium, potassium, and calcium regulation. Cardiovasc Drug Ther 1990; 4: 335–42

    Google Scholar 

  79. Falkner B. Differences in blacks and whites with essential hypertension: biochemistry and endocrine. Hypertens 1990; 15 (6 Pt 2): 681–6

    CAS  Google Scholar 

  80. Quintanilla AP, Wagener OE. Diuretics and cation transport in hypertensive blacks. Cardiovasc Drug Ther 1990; 4: 383–7

    Google Scholar 

  81. Harshfield GA, Alpert BS, Pulliam DA, et al. Sodium excretion and racial differences in ambulatory blood pressure patterns. Hypertens 1991; 18: 813–8

    CAS  Google Scholar 

  82. Falkner B, Kushner H. Effect of chronic sodium loading on cardiovascular response in young blacks and whites. Hypertens 1990; 15: 36–43

    CAS  Google Scholar 

  83. Luft FC, Miller JS, Grim CE, et al. Salt sensitivity and resistance of blood pressure: age and race as factors in physiological responses. Hypertens 1991; 17 Suppl. 1:1102–8

    Google Scholar 

  84. Flack JM, Ensrud KE, Mascioli S, et al. Racial and ethnic modifiers of the salt-blood pressure response. Hypertens 1991; 17 Suppl. 1:1115–21

    Google Scholar 

  85. Campese VM, Parise M, Karubian F, et al. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertens 1991; 18: 805–12

    CAS  Google Scholar 

  86. Weir MR. The impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med 1991; 90 Suppl. 5A: 3S–14S

    PubMed  CAS  Google Scholar 

  87. Light KC, Turner JR. Stress-induced changes in the rate of sodium excretion in healthy black and white men. J Psychosom Res 1992; 36: 497–508

    PubMed  CAS  Google Scholar 

  88. Zemel MB, Gualdoni SM, Sowers JR. Reductions in total and extracellular water associated with calcium-induced natriuresis and the antihypertensive effect of calcium in blacks. Am J Hypertens 1988; 1: 70–2

    PubMed  CAS  Google Scholar 

  89. Weinberger MH. Metabolic considerations in the treatment of the black hypertensive. Clin Cardiol 1989; 12: IV82–6

    PubMed  CAS  Google Scholar 

  90. Veterans Administration Study Group on antihypertensive agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol 1983; 51: 1230–7

    Google Scholar 

  91. Stein M, O’Malley K, Kilfeather S. Ethnic differences in cyclic AMP accumulation: effect of alpha2, beta2, and prostanoid receptor responses. Clin Pharmacol Ther 1990; 47: 360–5

    PubMed  CAS  Google Scholar 

  92. M’Buyamba-Kabangu JR, Tambwe M. The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks. Cardiovasc Drug Ther 1990; 4: 389–94

    Google Scholar 

  93. Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther 1992; 51: 495–500

    PubMed  CAS  Google Scholar 

  94. Rutledge DR, Wallace A, Melchior W, et al. Racial differences in baseline cyclic adenosine monophosphate concentrations per million T-lymphocytes and protein concentrations. Ther Drug Monit 1990; 12: 541–6

    PubMed  CAS  Google Scholar 

  95. Dimsdale J, Ziegler M, Graham R. The effect of hypertension, sodium and race on isoproterenol sensitivity. Clin Exp Hypertens 1988; 10: 747–56

    CAS  Google Scholar 

  96. Joubert PH, Venter CP, Wellstein A. Ethnic differences in response to beta blockade: fact or artefact? A study with bisoprolol and propranolol. Eur J Clin Pharmacol 1988; 34: 363–8

    PubMed  CAS  Google Scholar 

  97. Cruickshank JK, Anderson N McF, Wadsworth J, et al. Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. BMJ 1984; 297: 1155–9

    Google Scholar 

  98. Freis ES, Materson B, Flamenbaum W Comparison of propranolol and hydrochlorthiazide in hypertension: evaluation of re-nin-angiotensin system. Am J Med 1983; 74: 1029–41

    PubMed  CAS  Google Scholar 

  99. Cruickshank JK, Beevers DG. Ethnic and geographic differences in blood pressure. In Bulpitt C, editor. Epidemiology of hypertension. Cambridge: Elsevier, 1985: 70–87

    Google Scholar 

  100. Wright Jr JT, DiPette DJ, Goodman RP, et al. Renin profile, race, and antihypertensive efficacy with atenolol and labetalol. J Human Hypertens 1991; 5: 193–8

    Google Scholar 

  101. Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320: 565–70

    PubMed  CAS  Google Scholar 

  102. Zhou HH, Wood AJJ. Increased suppression of exercise-induced increase in renin by propranolol in Chinese subjects. Clin Pharmacol Ther 1991; 50: 150–6

    PubMed  CAS  Google Scholar 

  103. Ajayi AA. Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. Afr J Med Med Sci 1991; 20: 123–4

    PubMed  CAS  Google Scholar 

  104. Cubeddu LX. Racial differences in response to antihypertensive drugs. J Clin Hypertens 1986; 3: 72S–78S

    Google Scholar 

  105. Hvidberg EF. Ethnic differences in phenytoin kinetics. Prog Clin Biol Res 1986; 214: 279–87

    PubMed  CAS  Google Scholar 

  106. Grasela TH, Sheiner LB, Rambeck B. Steady-state pharmaco-kinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983; 8: 355–64

    PubMed  CAS  Google Scholar 

  107. Leck I, Thomson JM, Bocaz JA, et al. A multi-centre study of coagulation and haemostatic variables during oral contraception: variations with geographical location and ethnicity. Int J Epidemiol 1991; 20: 913–20

    PubMed  CAS  Google Scholar 

  108. Guy RH, Tur E, Bierke S, et al. Are there age and racial differences to methyl nicotinate-induced vasodilation in human skin? J Am Acad Dermatol 1985; 12: 1001–4

    PubMed  CAS  Google Scholar 

  109. Berardesca E, Maibach HI. Racial differences in pharmacodynamic response to nicotinates in vivo in human skin: black and white. Acta Derm Venerol 1990; 70: 63–6

    PubMed  CAS  Google Scholar 

  110. Sumrani N, Delaney V, Hong JH, et al. Racial differences in renal transplant outcome of insulin-dependent diabetic recipients in the cyclosporine era. Trans Am Soc Artif Intern Organs 1991;37:M304–5

    CAS  Google Scholar 

  111. Lindholm A, Welsh M, Alton C, et al. Demographic factors influencing cyclosporine phamacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359–71

    PubMed  CAS  Google Scholar 

  112. Lawson WB. Racial and ethnic factors in psychiatric research. Hosp Commununity Psychiatry 1986; 37: 50–4

    CAS  Google Scholar 

  113. Adams GL, Dworkin RJ, Rosenberg SD. Diagnosis and pharmacotherapy issues in the care of Hispanics in the public sector. Am J Psychiatry 1984; 141: 970–4

    PubMed  CAS  Google Scholar 

  114. Potkin SG, Shen Y, Pardes H, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984; 12: 167–72

    PubMed  CAS  Google Scholar 

  115. Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8: 195–201

    CAS  Google Scholar 

  116. Kishimoto A, Hollister LE. Nortriptyline kinetics in Japanese and Americans. J Clin Psychopharmacol 1984; 4: 171–2

    PubMed  CAS  Google Scholar 

  117. Yang YY. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatr Scand 1985;71: 171–5

    PubMed  CAS  Google Scholar 

  118. Lin KM, Poland RE, Lesser IM. Ethnicity and psychopharmacology. Cult Med Psychiatry 1986; 10: 151–65

    PubMed  CAS  Google Scholar 

  119. Ziegler VE, Biggs JT. Tricyclic plasma levels: effect of age, race, sex, and smoking. JAMA 1977; 238: 2167–9

    PubMed  CAS  Google Scholar 

  120. Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry 1982; 43: 457–60

    PubMed  CAS  Google Scholar 

  121. Rudorfer MV, Lane EA, Potter WZ. Interethnic dissociation between debrisoquine and desipramine hydroxylation. J Clin Psychopharmacol 1985; 5: 89–92

    PubMed  CAS  Google Scholar 

  122. Allen JJ, Rack PH, Vaddadi KS. Differences in effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study. Postgrad Med J 1977; 53 Suppl. 4: 79–86

    PubMed  CAS  Google Scholar 

  123. Lewis P, Vaddadi KS, Rack PH, et al. Ethnic differences in drug response. Postgrad Med J 1980; 56 Suppl. 1: 46–9

    PubMed  Google Scholar 

  124. Bond WS. Ethnicity and psychotropic drugs. Clin Pharm 1990; 10: 467–70

    Google Scholar 

  125. Lin KM, Lau JK, Smith R, et al. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology 1988; 96: 365–9

    PubMed  CAS  Google Scholar 

  126. Zhang Y, Reviriego J, Lou Y-q, et al. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990; 48: 496–502

    PubMed  CAS  Google Scholar 

  127. Kumana CR, Lauder IJ, Chan M, et al. Differences in diazepam pharmacokinetics in Chinese and white Caucasians — relation to body lipid stores. Eur J Clin Pharmacol 1987; 32: 211–5

    PubMed  CAS  Google Scholar 

  128. Pi EH, Tran-Johnson TK, Walker NR, et al. Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol Bull 1989; 25: 483–7

    PubMed  CAS  Google Scholar 

  129. Pi EH, Tran-Johnson TK, Gray GE, et al. Saliva and plasma desipramine levels in Asian and Caucasian volunteers. Psychopharmacol Bull 1991; 27: 281–4

    PubMed  CAS  Google Scholar 

  130. Kroll J, Linde P, Habenicht M, et al. Medication compliance, antidepressant blood levels, and side effects in Southeast Asian patients. J Clin Psychopharmacol 1990; 10: 279–83

    PubMed  CAS  Google Scholar 

  131. Kinzie JD, Leung P, Boehnlein JK, et al. Antidepressant blood levels in Southeast Asians: clinical and cultural implications. J Nerv Ment Dis 1987; 175: 480–5

    PubMed  CAS  Google Scholar 

  132. Honda Y, Suzuki T. Transcultural pharmacokinetic study on Li concentration in plasma and saliva. Psychopharmacol Bull 1979; 15 (4): 37–9

    PubMed  CAS  Google Scholar 

  133. Takahashi R. Lithium treatment in affective disorders: therapeutic plasma level. Psychopharmacol Bull 1979; 15 (4): 32–5

    PubMed  CAS  Google Scholar 

  134. Shelley RK. Are there ethnic differences in lithium pharmacokinetics and side effects? Int Clin Psychopharmacol 1987; 2: 337–42

    PubMed  CAS  Google Scholar 

  135. Lin K, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983; 140: 490–1

    PubMed  CAS  Google Scholar 

  136. Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981; 138: 1243–4

    PubMed  CAS  Google Scholar 

  137. Raskin A, Crook TH. Antidepressants in black and white inpatients: differential respone to a controlled trial of chlorpromazine and imipramine. Arch Gen Psychiatry 1975; 32: 643–9

    PubMed  CAS  Google Scholar 

  138. Lin KH, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989; 146: 1307–11

    PubMed  CAS  Google Scholar 

  139. Jann MW, Chang WH, Davis CM, et al. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res 1989; 30: 45–52

    PubMed  CAS  Google Scholar 

  140. Jann MW, Chang WH, Lam YWF, et al. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 193–202

    PubMed  CAS  Google Scholar 

  141. Chang WH, Chen TY, Leed CF, et al. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients. Biol Psychiatry 1987; 22: 1406–8

    PubMed  CAS  Google Scholar 

  142. Chang WH, Jann MW, Hwu HG, et al. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese. J Formos Med Assoc 1991; 90: 572–8

    PubMed  CAS  Google Scholar 

  143. Sane DC, Stump DC, Topoi EJ, et al. Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Circulation 1991; 83: 170–5

    PubMed  CAS  Google Scholar 

  144. Strickland TL, Ranganath V, Lin KM, et al. Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacol Bull 1991; 27 (4): 441–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Associates in Business and Research (ABR), Maison des Truites, CH-1182, Gilly, Switzerland

    Mary Ellen Kitler

Authors
  1. Mary Ellen Kitler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitler, M.E. Clinical Trials and Transethnic Pharmacology. Drug-Safety 11, 378–391 (1994). https://doi.org/10.2165/00002018-199411050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199411050-00005

Keywords

Search

Navigation